AB&B Bio-Tech Reports Stable Share Capital and Full Public Float Compliance in March 2026 Update

Bulletin Express18:42

AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.

Authorised and registered capital remained at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1. The issued share structure was unchanged: 296.36 million H shares and 97.08 million domestic shares, with no treasury stock on the company’s balance sheet.

The filing also affirms that the minimum 25 percent public-float requirement under Hong Kong Listing Rules was fully met as at 31 March 2026. No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases or other treasury-share movements during the month.

The statement was authorised by Executive Director Li Runxiang and submitted to Hong Kong Exchanges and Clearing Limited on 9 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107515918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107515918","market":"hk","top_or_hot":-1,"title":"AB&B Bio-Tech Reports Stable Share Capital and Full Public Float Compliance in March 2026 Update","media":"Bulletin Express","content":"<p>AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.</p>\n<p>Authorised and registered capital remained at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1. The issued share structure was unchanged: 296.36 million H shares and 97.08 million domestic shares, with no treasury stock on the company’s balance sheet.</p>\n<p>The filing also affirms that the minimum 25 percent public-float requirement under Hong Kong Listing Rules was fully met as at 31 March 2026. No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases or other treasury-share movements during the month.</p>\n<p>The statement was authorised by Executive Director Li Runxiang and submitted to Hong Kong Exchanges and Clearing Limited on 9 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech Reports Stable Share Capital and Full Public Float Compliance in March 2026 Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech Reports Stable Share Capital and Full Public Float Compliance in March 2026 Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.</p>\n<p>Authorised and registered capital remained at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1. The issued share structure was unchanged: 296.36 million H shares and 97.08 million domestic shares, with no treasury stock on the company’s balance sheet.</p>\n<p>The filing also affirms that the minimum 25 percent public-float requirement under Hong Kong Listing Rules was fully met as at 31 March 2026. No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases or other treasury-share movements during the month.</p>\n<p>The statement was authorised by Executive Director Li Runxiang and submitted to Hong Kong Exchanges and Clearing Limited on 9 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1107515918","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107515918","pubTimestamp":1775731354,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"AB&B Bio-Tech报告2026年3月股本稳定且公众持股量完全合规更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"AB&B Bio-Tech (02627) disclosed its Monthly Return for the period ended 31 March 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.\nAuthorised and registered capital remained at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1. The issued share structure was unchanged: 296.36 million H shares and 97.08 million domestic shares, with no treasury stock on the company’s balance sheet.\nThe filing also affirms that the minimum 25 percent public-float requirement under Hong Kong Listing Rules was fully met as at 31 March 2026. No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or outstanding, and there were no share repurchases or other treasury-share movements during the month.\nThe statement was authorised by Executive Director Li Runxiang and submitted to Hong Kong Exchanges and Clearing Limited on 9 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107515918","isCrawlerRequest":true}